Tecan Spark® Cyto to Empower CORE Oncology Research (791-19)
UNITED KINGDOM / AGILITYPR.NEWS / December 12, 2019 / Congratulations to Christophe Deben and the team at the University of Antwerp's Center for Oncological Research (CORE) on winning a fully loaded Tecan Spark® Cyto plate reader with live cell imaging and real-time cytometry. This competition, which ran from April to September 2019, required labs to submit a written proposal explaining how they would use the system to further their research and advance scientific understanding. A shortlist was selected from a strong field of over 100 entries by a panel of expert judges, and each finalist was invited to give a short webinar presentation providing further details of their planned research.
Christophe's winning proposal described how he would use the Spark Cyto to investigate the influence of oxygen levels on chemotherapy-induced CD70 expression and antibody-dependent cellular cytotoxicity in non-small cell lung cancer cells. The judges were impressed by both the scope of this proposal and Christophe's vision of how the unique features of the Spark Cyto could contribute to the growing field of immuno-oncology.
Christophe commented: "I’m very pleased to have been selected as the winner of this competition. When writing the project proposal, I let my imagination run wild in creating the experimental set-up, and it amazes me that nearly everything I thought of is possible with the Spark Cyto! The versatility of the instrument means that we will be able to use it for nearly every line of research running at CORE, and I can’t wait to start working with it and discover all of its capabilities."
To find out more about the Spark Cyto, visit www.tecan.com/sparkcyto
All Tecan products mentioned are for research use only. Not for use in clinical diagnostics.
Photo: The CORE received its Spark Cyto system in early December.
About Us
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2018, Tecan generated sales of CHF 594 million (USD 606 million; EUR 516 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
Über Tecan
Tecan (www.tecan.com) ist ein weltweit führender Anbieter von Laborinstrumenten und Lösungen für die Branchen Biopharma, Forensik und Klinische Diagnostik. Das Unternehmen ist auf Entwicklung, Herstellung und Vertrieb von Automatisierungslösungen für Laboratorien im Life-Science-Bereich spezialisiert. Die Kunden von Tecan sind Pharma- und Biotechnologieunternehmen, Forschungs-abteilungen von Universitäten sowie forensische und diagnostische Laboratorien. Als Originalgeräte-hersteller (OEM) ist Tecan auch führend in der Entwicklung und Herstellung von OEM-Instrumenten und Komponenten, die vom jeweiligen Partnerunternehmen vertrieben werden. Tecan wurde 1980 in der Schweiz gegründet. Das Unternehmen verfügt über Produktions-, Forschungs- und Entwicklungs-stätten in Europa und in Nordamerika. In 52 Ländern unterhält es ein Vertriebs- und Servicenetz. Im Jahr 2016 erzielte Tecan einen Umsatz von CHF 594 Mio. (USD 606 Mio.; EUR 516 Mio.). Die Namenaktien der Tecan Group werden an der SIX Swiss Exchange gehandelt (TECN; ISIN CH0012100191).
Contacts
Sarah Ballard
ideas@kdm-communications.comKDM Communications Limited, St Neots, UK
Phone: +44 1480 405333